← All trials
NCT05861778
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 26, 2023
- Primary completion
- Nov 27, 2023
- Completion date
- Nov 27, 2023
- First posted
- May 17, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TelixLead sponsor
- Peking UniversityOverall official - principal investigator
- Grand Pharma (China) Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.